KMDA

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.14
Percentage change 1.81	%

Peers: ALNY BMRN BCRX CERS NVAX APVO XTLB CTMX AKTX ITOS

| Held by: DFIS DFIC DISV DFAX

Scroll to Statements

Index	-	P/E	28.20	EPS (ttm)	0.28	Insider Own	45.96%	Shs Outstand	57.51M	Perf Week	-0.25%
Market Cap	453.18M	Forward P/E	20.03	EPS next Y	0.39	Insider Trans	0.00%	Shs Float	31.08M	Perf Month	17.09%
Enterprise Value	388.03M	PEG	1.07	EPS next Q	0.09	Inst Own	14.72%	Short Float	0.42%	Perf Quarter	17.44%
Income	16.06M	P/S	2.71	EPS this Y	23.59%	Inst Trans	-8.08%	Short Ratio	1.51	Perf Half Y	31.55%
Sales	167.24M	P/B	1.80	EPS next Y	20.10%	ROA	4.47%	Short Interest	0.13M	Perf YTD	29.39%
Book/sh	4.38	P/C	5.94	EPS next 5Y	26.39%	ROE	6.44%	52W High	9.15 -13.93%	Perf Year	63.15%
Cash/sh	1.33	P/FCF	12.41	EPS past 3/5Y	- -14.54%	ROIC	6.15%	52W Low	5.08 55.12%	Perf 3Y	75.89%
Dividend Est.	-	EV/EBITDA	10.06	Sales past 3/5Y	15.80% 4.82%	Gross Margin	44.23%	Volatility	2.30% 2.54%	Perf 5Y	-9.84%
Dividend TTM	0.20 (2.54%)	EV/Sales	2.32	EPS Y/Y TTM	16.61%	Oper. Margin	14.60%	ATR (14)	0.21	Perf 10Y	80.32%
Dividend Ex-Date	Mar 17, 2025	Quick Ratio	1.93	Sales Y/Y TTM	11.83%	Profit Margin	9.60%	RSI (14)	69.92	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.30	EPS Q/Q	67.64%	SMA20	7.30%	Beta	0.95	Target Price	14.75
Payout	0.00%	Debt/Eq	0.04	Sales Q/Q	16.65%	SMA50	12.56%	Rel Volume	0.27	Prev Close	7.74
Employees	420	LT Debt/Eq	0.04	Earnings	May 14 BMO	SMA200	21.61%	Avg Volume	86.28K	Price	7.88
IPO	May 31, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.30% 4.24%	Trades		Volume	23,331	Change	1.81%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-21-25	Initiated	The Benchmark Company	Buy	$15
Jul-03-24	Initiated	Stifel	Buy	$18
Feb-02-18	Initiated	Chardan Capital Markets	Buy	$7

Jul-04-25 11:40AM	KMDA or ACAD: Which Is the Better Value Stock Right Now? (Zacks)
09:40AM	Is Kamada (KMDA) Stock Undervalued Right Now? (Zacks)
Jun-25-25 11:14AM	Strength Seen in Kamada (KMDA): Can Its 9.5% Jump Turn into More Strength? (Zacks)
Jun-18-25 11:40AM	KMDA vs. ACAD: Which Stock Is the Better Value Option? (Zacks)
09:40AM	Should Value Investors Buy Kamada (KMDA) Stock? (Zacks)
07:00AM	Loading…
Jun-17-25 07:00AM	Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East (GlobeNewswire)
Jun-10-25 10:21AM	Implied Volatility Surging for Kamada Stock Options (Zacks)
Jun-02-25 09:55AM	Wall Street Analysts Think Kamada (KMDA) Could Surge 106.86%: Read This Before Placing a Bet (Zacks)
09:40AM	Are Investors Undervaluing Kamada (KMDA) Right Now? (Zacks)
May-28-25 11:40AM	KMDA vs. CSLLY: Which Stock Should Value Investors Buy Now? (Zacks)
May-16-25 09:55AM	Wall Street Analysts Believe Kamada (KMDA) Could Rally 106.56%: Here's is How to Trade (Zacks)
09:40AM	Is Kamada (KMDA) Stock Undervalued Right Now? (Zacks)
May-14-25 09:30AM	Compared to Estimates, Kamada (KMDA) Q1 Earnings: A Look at Key Metrics (Zacks)
08:10AM	Kamada (KMDA) Q1 Earnings Match Estimates (Zacks)
07:00AM	Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability (GlobeNewswire)
08:50AM	Loading…
May-13-25 08:50AM	XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates (Zacks)
May-09-25 09:15AM	Kamada (KMDA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks)
May-08-25 05:55PM	Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates (Zacks)
May-07-25 06:35PM	Nuvation Bio Inc. (NUVB) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025 (GlobeNewswire)
May-06-25 07:10PM	Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates (Zacks)
May-05-25 07:00AM	Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM (GlobeNewswire)
Mar-24-25 07:00AM	Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders (GlobeNewswire) +5.65%
Mar-19-25 07:00AM	Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas (GlobeNewswire)
Mar-18-25 09:00AM	Sidoti Events, LLC's Virtual March Small-Cap Conference (ACCESSWIRE)
Mar-05-25 07:05AM	Kamada Reports Record Top and Bottom Line 2024 Financial Results and Affirms 2025 Guidance Representing Double-Digit Profitable Growth (GlobeNewswire) +7.41%
07:00AM	Kamada Declares Special Cash Dividend of $0.20 Per Share (GlobeNewswire)
Feb-26-25 07:00AM	Kamada to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 5, 2025 (GlobeNewswire)
Jan-23-25 07:14AM	Kamada to supply immune globulin products in Latin America (Pharmaceutical Business Review) -5.31%
Jan-22-25 07:00AM	Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB and VARIZIG in Latin America (GlobeNewswire) +6.36%
07:29AM	Loading…
Jan-09-25 07:29AM	Kamada Projects Double-Digit Growth for 2025, Expands Plasma Operations (TipRanks)
Jan-08-25 07:00AM	Kamada Affirms 2024 Financial Guidance and Announces Expected Continued Double-Digit Profitable Growth for 2025 (GlobeNewswire) +7.65%
Nov-13-24 07:00AM	Kamada Reports Continued Profitable Growth with Strong Third Quarter and Nine Month 2024 Financial Results; Raises Full-Year Profitability Guidance (GlobeNewswire)
Nov-06-24 07:00AM	Kamada to Announce Third Quarter and Nine-Months Ended September 30, 2024 Financial Results and Host Conference Call on November 13, 2024 (GlobeNewswire)
Nov-04-24 07:00AM	Kamada to Present at the Stifel 2024 Healthcare Conference (GlobeNewswire)
Sep-23-24 07:00AM	Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston (GlobeNewswire)
Aug-14-24 07:00AM	Kamada Reports Strong Second Quarter and First Half 2024 Financial Results with Year-Over-Year 6-Month Top-Line Growth of 18% and a 68% Increase in Profitability (GlobeNewswire)
Aug-07-24 07:00AM	Kamada to Announce Second Quarter and First Half Ended June 30, 2024 Financial Results and Host Conference Call on August 14, 2024 (GlobeNewswire)
Jul-29-24 03:04PM	3 Promising Biotech Stocks You Can Pick Up for Less Than $10 (InvestorPlace)
May-08-24 11:57AM	KMDA Stock Earnings: Kamada Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:00AM	Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance (GlobeNewswire)
May-01-24 07:00AM	Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 (GlobeNewswire)
Mar-06-24 12:52PM	KMDA Stock Earnings: Kamada Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace) -5.02%
07:05AM	Kamada Issues 2024 CEO Letter to Shareholders (GlobeNewswire)
07:00AM	Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability (GlobeNewswire)
Feb-28-24 07:00AM	Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024 (GlobeNewswire)
Dec-07-23 11:00AM	KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB (PR Newswire)
Dec-06-23 07:00AM	Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB including $180 Million of Revenues Over First Four Years (GlobeNewswire) +20.87%
Nov-13-23 07:00AM	Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance (GlobeNewswire)
Nov-08-23 07:00AM	Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023 (GlobeNewswire)
Oct-16-23 07:00AM	Kamada Announces Recent Achievements with CYTOGAM including Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data (GlobeNewswire)
Oct-10-23 07:37AM	Kamada Provides Corporate Update on its Israel Operations (GlobeNewswire)
Aug-30-23 07:00AM	Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds (GlobeNewswire)
Aug-16-23 07:00AM	Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance (GlobeNewswire)
Aug-09-23 07:00AM	Kamada to Announce Second Quarter and First Half Ended June 30, 2023 Financial Results and Host Conference Call on August 16, 2023 (GlobeNewswire)
Jul-12-23 07:00AM	Kamada Announces Kedrion Exercised its Option for Two-Year Extension of KEDRAB® Distribution Agreement in the U.S. (GlobeNewswire)
May-24-23 07:10AM	Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance (GlobeNewswire) +15.38%
07:05AM	Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary (GlobeNewswire)
07:00AM	Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds (GlobeNewswire)
May-17-23 07:00AM	Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023 (GlobeNewswire)
May-16-23 07:00AM	Kamada Announces Receipt of Marketing Authorization for Glassia® for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland (GlobeNewswire)
May-03-23 07:00AM	Kamada Announces U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Companys Facility in Israel (GlobeNewswire)
Mar-15-23 07:10AM	Kamada Issues 2023 CEO Letter to Shareholders (GlobeNewswire)
07:00AM	Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth (GlobeNewswire)
Mar-09-23 08:00AM	Kamada to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 15, 2023 (GlobeNewswire)
Jan-04-23 07:00AM	Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Companys Facility in Israel (GlobeNewswire)
Dec-19-22 07:00AM	Kamada Announces Planned Transition of Chief Financial Officer (GlobeNewswire) +7.46%
Dec-15-22 09:07AM	Wave Life Sciences (WVE) Up 26% on Collaboration With GSK (Zacks) -6.24%
Dec-02-22 10:54AM	Valneva (VALN) Up on 6-Month Lyme Disease Jab Persistence Data (Zacks)
Nov-28-22 07:39AM	New Strong Buy Stocks for November 28th (Zacks)
Nov-23-22 11:42AM	AcuCort signs its first commercial agreement for the company's drug Zeqmelit (PR Newswire)
Nov-22-22 08:25AM	Kamada (KMDA) Q3 Earnings and Revenues Top Estimates (Zacks)
07:00AM	Kamada Reports Strong Third Quarter Financial Results Demonstrating Successful Strategic Transition and Reiterates 2022 Financial Guidance (GlobeNewswire)
Nov-16-22 07:00AM	Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2022 Financial Results and Host Conference Call on November 22, 2022 (GlobeNewswire)
Nov-10-22 05:25PM	Science 37 Holdings, Inc. (SNCE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-07-22 07:00AM	Kamada Provides Update on Recent Progress Achieved in Ongoing Pivotal Phase 3 Clinical Trial of Inhaled AAT (GlobeNewswire)
Oct-26-22 07:00AM	Kamada to Present at the Credit Suisse 31st Annual Healthcare Conference (GlobeNewswire)
Oct-19-22 07:00AM	Kamada Awarded $22 Million Extension of Canadian Supply Tender (GlobeNewswire)
Oct-12-22 12:11PM	Vertex Pharmaceuticals' (VRTX) New AAT Corrector Enters Clinic (Zacks)
Sep-22-22 01:28PM	Eli Lilly (LLY) Gets FDA Nod for RET Inhibitor in Solid Tumors (Zacks)
Sep-20-22 12:10PM	AbbVie (ABBV) Gets CHMP Nod for Skyrizi in a Third Indication (Zacks)
Sep-19-22 12:28PM	Sanofi (SNY) Gets CHMP Nod for Enjaymo in Hemolytic Anemia (Zacks)
12:21PM	Merck's (MRK) Pneumococcal Jab Gets CHMP Endorsement for Kids (Zacks)
Sep-16-22 11:42AM	Eloxx (ELOX) Down After Cystic Fibrosis Study Fails to Meet Goal (Zacks)
Sep-14-22 01:09PM	Clovis (CLVS) Seeks Nod for Rubraca in First Line Ovarian Cancer (Zacks)
Sep-13-22 11:24AM	FDA Panel to Review Perrigo's (PRGO) OTC Birth Control Pill (Zacks)
Sep-09-22 12:23PM	Amylyx (AMLX) Up 51% After FDA Committee Endorses ALS Drug (Zacks)
Aug-17-22 08:25AM	Kamada (KMDA) Q2 Earnings Beat Estimates (Zacks)
07:00AM	Kamada Reports Second Quarter and First Half 2022 Financial Results; Significant Growth Driven by Multiple Catalysts Expected in Second Half of 2022; Reiterates 2022 Revenue and Profitability Guidance (GlobeNewswire)
Aug-15-22 08:15AM	Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-10-22 07:00AM	Kamada to Announce Second Quarter and First Half Ended June 30, 2022 Financial Results and Host Conference Call on August 17, 2022 (GlobeNewswire)
Jul-15-22 07:00AM	Kamada Announces Resolution to the Labor Strike at the Companys Manufacturing Facility in Israel; A New, Eight-Year Collective Agreement Signed (GlobeNewswire)
Jul-06-22 06:00AM	Kamada Announces $11.4 Million International VARIZIG® Procurement Agreement (GlobeNewswire)
Jun-15-22 07:00AM	Kamada Strengthens Senior Leadership Team; Furthering Commitment as a Fully Integrated Global Leader in the Specialty Plasma-Derived Therapeutics Market (GlobeNewswire)
Jun-01-22 07:00AM	Kamada to Host a Virtual Analysts and Investors Meeting to Review its Growth Catalysts (GlobeNewswire)
May-17-22 08:25AM	Kamada (KMDA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:05AM	Kamada Reports First Quarter 2022 Financial Results; Reiterates Revenue and Profitability Guidance with Significant Growth Expected in 2022 (GlobeNewswire)
07:00AM	Kamada Announces Expansion of Pivotal Phase 3 Clinical Trial of Inhaled AAT to Additional Six Clinical Sites Across Europe; and Positive Recommendation by DSMB to Continue the Trial Without Modification (GlobeNewswire)
May-11-22 07:00AM	Kamada to Announce First Quarter Ended March 31, 2022 Financial Results and Host Conference Call on May 17, 2022 (GlobeNewswire)
Mar-15-22 07:05AM	Kamada Issues 2022 CEO Letter to Shareholders (GlobeNewswire)

Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Kamada Ltd

Upgrade your FINVIZ experience